You are viewing the site in preview mode
Skip to main content
|
Patients previously treated with two treatment lines
|
Cetuximab group (n = 23)
|
BSC group (n = 35)
|
P values
|
|---|
|
Male
|
60%
|
65%
|
NS (p = 0.16)
|
|
Age, median (years)
|
64
|
60
|
p < 0.05
|
|
PS
|
0
|
26%
|
6%
|
p < 0.05
|
|
1
|
17%
|
11%
|
|
2
|
9%
|
3%
|
|
3
|
–
|
–
|
|
4
|
4%
|
–
|
|
Unknown
|
43%
|
80%
|
|
Location
|
Colon
|
48%
|
54%
|
NS (p = 0.9)
|
|
Rectum
|
35%
|
31%
|
|
Rectosigmoid
|
13%
|
9%
|
|
Unknown
|
4%
|
6%
|
|
Charlson Indexa
|
6
|
35%
|
63%
|
NS (p = 0.1)
|
|
7
|
35%
|
17%
|
|
8
|
17%
|
11%
|
|
9
|
–
|
6%
|
|
10
|
9%
|
–
|
|
Unknown
|
4%
|
3%
|
|
Mean total treatment duration (days)
|
398
|
264
|
p < 0.05
|
|
Mean treatment duration prior to BSC or cetuximab (days)
|
268
|
264
|
NS (p = 0.9)
|
- BSC best supportive care, NS not significant, PS performance status
- aSeverity as scored with the Charlson Index; the presence of mCRC leads to an automatic score of 6 as baseline
